The largest M&A deal in the history of South Korea's pharmaceutical industry is coming.
A CHF 1.46 billion merger and acquisition deal is set to reshape the global CDMO competitive landscape.
Recently, Samsung Biologics launched a public tender offer for the Swiss listed company PolyPeptide Group AG, offering a price of CHF 44.31 per share, which is approximately 40% higher than the unaffected share price. Following this, it will acquire all shares via an all-cash transaction. This deal is widely regarded as the largest M&A transaction in the history of South Korea's pharmaceutical and biotech industries.
Samsung Biologics previously concentrated most of its production capacity within South Korea, and overseas expansion has long been one of its weaknesses. PolyPeptide operates six manufacturing facilities across five countries, with over 70 years of expertise in producing active pharmaceutical ingredients (APIs) for peptides. This is not a simple matter of expanding production capacity, but a full-scale global layout. How this transaction will alter the position of Asian CDMOs worldwide is what deserves our close attention.
The Largest M&A Deal in Pharmaceutical History
With this single transaction, Samsung Biologics' global footprint has been completely transformed.
Recently, Samsung Biologics made a public tender offer to PolyPeptide Group AG, offering CHF 44.31 per share, roughly 25% higher than the unaffected share price. At this price, the total value of the equity being transacted is approximately CHF 1.46 billion, equivalent to around USD 1.81 billion and about RMB 12.2 billion. The acquisition is structured as an all-cash deal to secure 100% ownership of the target company. This transaction is recognized as the largest M&A activity in the history of South Korea's pharmaceutical and biotech sectors, and it also marks Samsung Biologics' most significant overseas expansion investment since its establishment. JPMorgan Chase acted as the sole financial advisor for the entire process, with no performance clauses or share swaps involved, making it a highly smooth and completed transaction.
PolyPeptide is no ordinary peptide contract manufacturer. The company was founded in 1996 through a spin-off of Ferring Pharmaceuticals' peptide business, and its origins in API production can be traced back more than 70 years. Over the decades, it has produced thousands of therapeutic peptide products, employs more than 1,500 people globally, and operates six production sites located in Malmö, Sweden; Boucherville, Belgium; Strasbourg, France; Torrance and San Diego, USA; and Ambernath, India. The Strasbourg site also hosts an innovation center dedicated to early-stage R&D for new processes and novel molecules. This production network spanning five countries represents the core value of the deal, as assets of this scale would have been impossible for Samsung Biologics to replicate quickly through greenfield construction on its own.
Prior to this, Samsung Biologics' production capacity was primarily concentrated in the Songdo region of South Korea, where it operates one of the world's largest single-site biopharmaceutical CDMO manufacturing bases, maintaining a geographically unipolar presence. If this M&A is successfully completed, Samsung Biologics will simultaneously hold facilities on the US East and West Coasts, production lines across three European countries, and a site in India, evolving from a regional powerhouse into a truly global enterprise capable of providing more convenient services to customers in Europe, America, and South Asia.
John Rim, CEO of Samsung Biologics, stated in the announcement that in addition to enabling the company to expand its modality coverage in peptide fields such as GLP-1, this acquisition will also enhance its service capabilities across the United States, Europe, and India to a certain extent. This statement clarifies two core objectives of the transaction: first, to expand its product portfolio, and second, to supplement its global service network — the latter being a key gap that Samsung Biologics previously lacked. Production capacity, product portfolio, and global layout have long been the three pillars of growth that Samsung Biologics has publicly emphasized, and this transaction has essentially completed the remaining two pillars.
The speed of the transaction execution is also noteworthy. PolyPeptide's largest shareholder, holding approximately 55.65% of the shares, has signed an irrevocable tender commitment letter. According to the current timeline, the formal offer is expected to be launched around August, with the entire transaction process likely to conclude by the end of the year. For a company that previously had a weak overseas presence, such rapid progress and transaction structure itself convey a message of near-certain success, prompting the industry to re-evaluate Samsung Biologics' future position in the global market.
The Vision from Antibodies to Peptides
To understand the full significance of this deal, we must trace back to Samsung Biologics' own development journey.
The company initially focused on the large-molecule antibody CDMO business. After constructing its massive production base in Songdo, South Korea, it gradually secured a favorable position in the global biopharmaceutical contract manufacturing market. In recent years, Samsung Biologics has not limited itself to antibody products, but continuously expanded its business scope into fields such as mRNA and ADC, with each expansion accompanied by new production capacity construction and technology accumulation. Now, with the addition of peptides, the company has completed a modality expansion chain covering antibodies, mRNA, ADCs, and finally peptides. The logic behind this path is clear: the more types of drugs a CDMO enterprise can accept orders for, the higher customer stickiness and greater negotiation leverage it will have. When customers become accustomed to outsourcing all types of production to a single supplier, their switching costs will continue to rise.
Demand in the peptide track is being rapidly unleashed. GLP-1 class weight-loss drugs are gaining increasing global attention, driving the continuous expansion of the entire peptide drug market. Industry forecasts indicate that the global obesity treatment market will reach approximately USD 150 billion by 2035. At the same time, the application scope of peptide drugs has gradually expanded from the initial metabolic disease sector to areas such as oncology, immunological diseases, and Alzheimer's disease, with more pharmaceutical companies beginning to incorporate peptide molecules into their early-stage research pipelines. There is no uncertainty about the demand-side potential; the real winners will be those with strong supply-side capabilities.
The peptide synthesis process is relatively complex, requiring large volumes of organic solvents, and the environmental protection and compliance certification cycles are extremely long. If an enterprise builds a production line from scratch, it will take more than three years to achieve stable and large-scale supply capacity, during which multiple process validations and customer audits are required. One of PolyPeptide's core technologies is a synthesis method that can significantly reduce the consumption of organic solvents, and the company holds an extensive pipeline of late-stage peptide projects, with many products approaching commercialization. For Samsung Biologics, acquiring a technologically mature enterprise with a complete pipeline is almost the only viable way to quickly fill its gap in the peptide field, skipping the years-long ramp-up process through a single transaction.
It is also worth noting that in addition to production capacity and technology, this transaction will bring ready-made commercial relationships. The long-accumulated customer contracts and CDMO order backlog of PolyPeptide will be transferred along with the acquisition, generating stable revenue immediately after the deal closes without requiring a lengthy incubation period — a rare level of certainty for any M&A transaction. Samsung Biologics will also leverage this foundation to implement cross-selling: enterprises engaged in both antibody and peptide drug R&D will be able to procure all services in one place, consolidating orders that were previously scattered across different suppliers. The shift from one-off transactions to long-term customer relationships is one of the core reasons why this acquisition can continuously create value, and it is also the fundamental motivation behind Samsung Biologics' emphasis on this deal.
Global CDMO Layout
Against the broader industry backdrop, the significance of Samsung Biologics' move becomes even more profound.
There is solid reasoning behind the industry's recognition of this transaction as the largest acquisition in South Korea's pharmaceutical and biotech history. Over the past few decades, South Korea's pharmaceutical industry's overseas expansion has primarily focused on pipeline-level collaborations, without involving the integration of global production capabilities. As a result, enterprises mostly pushed new drugs to international markets through licensing-out models, rather than acquiring complete overseas production bases. What Samsung Biologics has purchased this time is not just factories, production lines, or personnel, but the integrated operational capability of an entire overseas production system. Going forward, Asian CDMOs will no longer be mere order takers, but will begin to move towards global asset M&A, using capital to gain advantages in both time and space.
Over the past decade, the center of gravity of the global CDMO industry has gradually shifted to Asia. Leading Chinese companies have established complete global production systems in Europe and America through multiple overseas acquisitions and greenfield construction, with their production capacity and delivery efficiency continuously improving. Enterprises from countries like South Korea and India have also built solid foundations in their respective fields, forming their own unique competitive advantages in niche segments. Samsung Biologics previously focused its development domestically, with overseas production capacity remaining a notable weakness. This transaction immediately addresses this shortcoming, allowing Samsung Biologics to formally join the competition for global production layout, evolving from a follower to one of the industry leaders.
In the overall peptide CDMO market, pharmaceutical companies previously had several main categories of outsourcing suppliers: specialized European and American peptide enterprises, the peptide business lines of Chinese CDMOs, and Indian manufacturers, each forming their own comparative advantages based on differences in cost, process, or geographic location. Samsung Biologics was not part of this competitive landscape before, but this acquisition directly brings it into the arena with six production sites across five countries and thousands of different peptide product production lines. Combined with its existing large-molecule customer sales channel network, the potential for cross-selling is greatly expanded, adding a major new variable to the previously relatively stable competitive environment.
For the entire CDMO industry, the dimensions of competition are quietly changing. Previously, competition was focused on production capacity scale and pricing, but now the key differentiators are the extent of global layout and the completeness of service models. Only by ensuring stable supply across multiple countries can companies secure orders from large customers who prioritize supply chain security. The application scope of peptide drugs continues to expand, from the initial metabolic disease field to oncology, immunological diseases, and neurological disorders, leaving enormous room for growth in the entire track. Samsung Biologics' move may only be the beginning of a wave of global integration, and many other Asian CDMO companies will likely adopt similar strategies to participate in the global competition, expanding their footprint across the world.
This article is from the WeChat public account "Rongzhong Finance" (ID: thecapital), author: LYU Jingzhi, published with authorization from 36Kr.